As ordered reported by the House Committee on Oversight and Government Reform on May 23, 2018, with a subsequent amendment provided to CBO on June 13, 2018
H.R. 5925 would authorize appropriations for the operations of the Office of National Drug Control Policy (ONDCP) and change the office’s name to the Office of National Drug Control (ONDC). The bill would authorize appropriations for programs administered by that office and for other federal anti-drug programs through 2023. Major programs administered by the office include the High-Intensity Drug Trafficking Areas program, the Drug-Free Communities program, and the Emerging Threats and Media Campaign.
Assuming appropriation of the specified amounts, CBO estimates that implementing H.R. 5925 would cost about $1.7 billion over the 2019-2023 period. Of that total, $1.1 billion would result from amounts specifically authorized for the High-Intensity Drug Trafficking Areas program.
Enacting the bill would affect direct spending because it would allow ONDC to accept and spend monetary gifts; therefore, pay-as-you-go procedures apply. However, CBO estimates that the net effect on direct spending would be negligible. Enacting H.R. 5925 would not affect revenues.
CBO estimates that enacting H.R. 5925 would not significantly increase net direct spending or on-budget deficits in any of the four consecutive 10-year periods beginning in 2029.
H.R. 5925 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act.